“…We performed a gene co-expression network analysis to investigate the phenotypic change of genes associated with AMI (Kumari et al, 2012; Villa-Vialaneix et al, 2013). Twelve genes from the AMI and control groups were chosen as key regulatory genes (| Dif _ Kcore | > 30), and it was shown that there was a significant change in the expression pattern of genes in the AMI group (Supplement Table 5), namely CNN2 (calponin 2), CRYZ (quinone oxidoreductase), SULT1A1 (sulfotransferase 1A1), SULT1A2 (sulfotransferase 1A2), PRMT2 (protein arginine methyltransferase 2), ATP1B1 (ATPase, Na + /K + transporting, beta 1 polypeptide), CX3CR1 (CX3C chemokine receptor 1), GCH1 (GTP cyclohydrolase 1), INSIG1 (insulin-induced gene protein), CXCL5 (C-X-C motif chemokine 5), GBP3 (guanylate-binding protein 3) and HEG1 (heart development protein with EGF-like domains 1).We hypothesized that the 12 key regulatory genes are likely to be closely related to the occurrence and development of AMI (Figure 3).…”